What is hs-CRP and what does it mean for heart health? Atherosclerosis is an inflammatory disease as well as a cholesterol one. Cholesterol particles start the plaque and inflammation sustains it, which is why the third marker on our cardiovascular panel is hs-CRP, the high-sensitivity measure of C-reactive protein. It is absent from the standard lipid panel, invisible to the annual physical and one of the few numbers that predicts cardiovascular events independently of cholesterol.
- Hs-CRP measures low-grade systemic inflammation with an assay sensitive enough to read cardiovascular risk.
- It predicts cardiovascular events independently of cholesterol, which is why the JUPITER trial was built around it.
- Transient infections and flares raise it, so the trend across draws matters more than any single value.
- Unlike Lp(a), it responds to intervention. The quarterly audit tracks whether the intervention is working.
- Hs-CRP is on the quarterly panel, included in the flat $299 membership, four audits a year.
What the marker measures
C-reactive protein is a liver-made protein that rises with systemic inflammation. The standard CRP test detects the large elevations of acute infection. The high-sensitivity assay, hs-CRP, reads the mild chronic elevation that tracks with the atherosclerotic process itself, vascular inflammation, metabolic dysfunction and the low-grade inflammatory state that insulin resistance and visceral fat produce.
That distinction matters because the two tests are often confused. A standard CRP ordered for a fever says nothing about cardiovascular risk. An hs-CRP drawn during a cold or a dental flare will read falsely high. This is why a single value is less useful than the trend across quarterly draws and why our clinicians read the marker alongside the CBC and the full panel rather than in isolation.
Why it predicts risk independently of cholesterol
The JUPITER trial, published in the New England Journal of Medicine in 2008, enrolled apparently healthy people with normal LDL cholesterol and elevated hs-CRP and randomized them to rosuvastatin or placebo. The trial was stopped early because the statin group had dramatically fewer cardiovascular events. The design made a specific point. Among people whose cholesterol looked clean, elevated inflammation identified a population at real risk and treating it reduced that risk.
The clinical implication is that cholesterol and inflammation are two dials of the same disease process. A person with low LDL and high hs-CRP is not clean, they are at risk through a different mechanism. A person with moderate LDL and low hs-CRP is often less risky than their lipid panel suggests. Reading both together, which is what our panel does, is the honest cardiovascular picture.
Cholesterol starts the plaque and inflammation sustains it. The panel that answers the question reads both dials, not one.
What to do with a high number
Unlike Lp(a), hs-CRP is modifiable and it responds to intervention faster than almost any other cardiovascular marker. Weight loss, especially visceral fat loss, regular exercise, smoking cessation, sleep quality and periodontal health all lower hs-CRP measurably within one to two quarters. Statins lower it as well, independently of their cholesterol effect, which is part of why the JUPITER result was so large.
The quarterly cadence is what turns the marker into a management tool. A single hs-CRP drawn during a dental flare tells you nothing and a trend across four clean draws tells you exactly what your inflammatory state is doing. Our clinicians read the trend, not the flag and adjust the protocol at each audit.


Who should ask for it
The short list is anyone with a family history of early heart disease, metabolic syndrome, prediabetes or diabetes, central weight gain that will not move or an hs-CRP-informed family story that never got tested. It is particularly relevant for the Concierge Longevity Optimizer who wants the full cardiovascular picture rather than the screening one and for the high-deductible patient paying cash for labs who wants the comprehensive read at one defined fee.
For readers considering a GLP-1 for weight loss, hs-CRP is one of the markers that typically improves as visceral fat falls and the quarterly audit shows that improvement directly rather than asking you to trust the process.
Why the standard panel still skips it
The structural reason is the same one that keeps ApoB and Lp(a) off the standard lipid panel. In per-visit billing, each additional test is a line item and each visit that explains it is another receipt, so the comprehensive panel is ordered only when a patient or a persistent clinician argues for it. Inflammation is invisible to the patient and produces no symptom until an event, so it loses that argument every time.
The membership model removes the constraint. When the full panel is included in the flat fee and repeats every 90 days, the rational choice is the test that answers the question rather than the test that fits the visit and that is what the Biomarker Audit runs every quarter.
What the membership costs, stated plainly
The Cardiometabolic Optimization Membership is one flat $299 per month covering the clinical relationship and four quarterly Biomarker Audits a year. It starts with a two month commitment paid as a single $598 hold covering the first two months together, charged only once a clinician accepts you into care. If no clinician can accept you, the hold is released and you are never charged. Once accepted, the first two months are non-refundable. From month three the membership is month to month and you can cancel anytime.
Medication is a separate charge and it never flows through us. Any prescription is written to the pharmacy you choose and billed by that pharmacy at its own price. GoodLife Health sets nothing, sees nothing and takes nothing on that transaction. There is no molecule upcharge and no dose upcharge, ever. One flat fee for the doctor. Zero markup on the medicine. The eligibility check is free and takes a few minutes.
Frequently Asked Questions
What is hs-CRP?
High-sensitivity C-reactive protein, a blood marker of low-grade systemic inflammation measured with an assay sensitive enough to detect the mild elevations that track with cardiovascular risk. It is different from the standard CRP test used to check for acute infection.
What does a high hs-CRP mean for the heart?
Persistently elevated hs-CRP signals the low-grade inflammatory state that drives atherosclerosis. It predicts cardiovascular events independently of cholesterol. The interpretation belongs to the clinician reading your full panel, because transient infections also raise it.
Can hs-CRP be lowered?
Yes. Weight loss, exercise, smoking cessation, better sleep, gum health and statin therapy all lower hs-CRP. Unlike Lp(a), it responds to intervention, which is what makes it worth tracking quarterly.
Why has my doctor never tested hs-CRP?
The standard lipid panel does not include it and per-visit billing adds a line item for every test, so the panel that answers the question is rarely ordered unless symptoms argue hard enough to win.
Is hs-CRP included in the Biomarker Audit?
Yes. Hs-CRP is on the quarterly Cardiometabolic Optimization Panel alongside ApoB, Lp(a), fasting insulin, HbA1c, the lipid panel, thyroid and CBC, included in the flat $299 membership four times a year.
How much does the membership cost?
One flat $299 per month covering the doctor and four quarterly lab audits a year, after a two month start paid as one $598 charge covering the first two months together. Medication is billed by your pharmacy separately at pharmacy cost with zero markup.
One last thing
The inflammation dial is one draw away, it is on our panel every quarter and it responds to intervention fast enough that you see the change at the next audit. The eligibility check is free, takes a few minutes and never results in a charge unless a clinician accepts you into care.
Related Guides
- Why is ApoB more important than LDL for heart risk?
- What is Lp(a) and why has your doctor never tested it?
- Cardiometabolic Optimization: the definitive guide
- What a Biomarker Audit includes